Clinical Trials Logo

Clinical Trial Summary

To generate pilot data to investigate the potential to use in vivo iron- and neuromelanin-quantification as imaging tools for the diagnostic evaluation of movement disorders with predominant dystonia / parkinsonism. To this end we are planning to compare the MR imaging neuromelanin and iron-pattern and content in midbrain, striatum and further brain structures in clinically similar entities and respective, sex- and age-matched healthy controls.


Clinical Trial Description

Iron- or Neuromelanin-sensitive MR-imaging has not been consistently applied to the study of syndromes presenting with predominant dystonia/parkinsonism yet. We are planning to study the following groups, as they can often be very difficult to be distinguished from PD and in particular young-onset PD, on clinical grounds only:

- Dopa-responsive dystonia (DRD) can present similar to young-onset PD, but carries a completely different prognosis, necessitating different treatment requirements due to fundamentally different underlying physiology.

- Sporadic and Inherited dystonias (i.e. due to TorsinA (DYT1) and other gene mutations) often present with dystonia, particularly affecting the leg, which is clinically indistinguishable from young-onset PD.

- Young-onset PD, i.e. PD presenting with motor symptoms before 45 years of age, caused by a familiar gene mutation (PARKIN, Pink, DJ-1, PLA2G6, FBX07, ATP13A2, VPS13C, RAB39B, Lubag), often presents with predominant dystonia, particularly with leg-onset.

- NBIAs present with dystonia/parkinsonism: while basal ganglia iron accumulation is a known hallmark feature of the condition [3], the characteristics of neuromelanin regulation are unknown.

- Mitochondrial disease presenting with dystonia / parkinsonism (such as for example Leigh syndrome due to mutations in the Surf-1 gene or mutations m.3243A>G or POLG) [4]

- Respective age- and sex-matched healthy controls This study is designed to produce pilot data on these disease entities. By potentially accelerating the diagnostic process and identification of disease entities, neurologists might be able to deliver more selective and dedicated treatment.

Furthermore, combining Neuromelanin- and iron-specific imaging will offer the possibility to study the condition- specific dynamics of iron homeostasis in these rare conditions. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03572114
Study type Observational
Source University College, London
Contact Sebastian R Schreglmann, MD
Phone 0203448 8604
Email skgtsrs@ucl.ac.uk
Status Not yet recruiting
Phase
Start date July 1, 2018
Completion date July 1, 2021

See also
  Status Clinical Trial Phase
Completed NCT03388528 - Low Residue Diet Study in Mitochondrial Disease N/A
Completed NCT04378075 - A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy Phase 2/Phase 3
Completed NCT03678740 - Diagnostic Odyssey Survey 2
Recruiting NCT06051448 - Promoting Resilience in Stress Management (PRISM) and Clinical-focused Narrative (CFN) Pilot in Adults With Primary Mitochondrial Disease (PMD). Phase 1/Phase 2
Completed NCT02909400 - The KHENERGY Study Phase 2
Completed NCT02398201 - A Study of Bezafibrate in Mitochondrial Myopathy Phase 2
Completed NCT03857880 - Identification of New Candidate Genes in Patients With Mitochondrial Disease by High Resolution Chromosome Analysis on DNA Chip
Not yet recruiting NCT06450964 - Establishment of Reproductive Cohort and Prediction Model of Genetic Counseling for Mitochondrial Genetic Diseases
Completed NCT04165239 - The KHENERGYZE Study Phase 2
Completed NCT02284334 - Glycemic Index in Mitochondrial Disease
Recruiting NCT06080568 - Human Mitochondrial Stress-driven Obesity Resistance
Recruiting NCT06080581 - Mitochondrial Dysfunctions Driving Insulin Resistance
Recruiting NCT04802707 - Deoxynucleosides Pyrimidines as Treatment for Mitochondrial Depletion Syndrome Phase 2
Completed NCT04594590 - Natural History Study of SLC25A46 Mutation-related Mitochondriopathy
Completed NCT04580979 - Natural History Study of FDXR Mutation-related Mitochondriopathy
Withdrawn NCT03866954 - Trial of Erythrocyte Encapsulated Thymidine Phosphorylase In Mitochondrial Neurogastrointestinal Encephalomyopathy Phase 2
Recruiting NCT04113447 - Mitochondrial Donation: An 18 Month Outcome Study.
Enrolling by invitation NCT04734626 - CrCest Study in Primary Mitochondrial Disease
Completed NCT03832218 - Executive Function Disorders and Anxio-depressive Symptomatology in Children and Adolescents With Mitochondrial Pathologies N/A
Terminated NCT02473445 - A Long-term Extension of Study RP103-MITO-001 (NCT02023866) to Assess Cysteamine Bitartrate Delayed-release Capsules (RP103) in Children With Inherited Mitochondrial Disease Phase 2